William D Mallender

5PUBLICATIONS
64CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

|Apr 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers.

|May 06, 2025
CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors.

Katherine Lazarides, Justin L Engel, Michele Meseonznik

|Jan 31, 2025
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency.

Antoine Simoneau, Charlotte B Pratt, Hsin-Jung Wu

|Jan 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers.

Lauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt

Pageof 1

Frequent Collaborators

5 joint publications

Jannik N Andersen

5 joint publications

Douglas A Whittington

4 joint publications

Yi Yu

4 joint publications

Alan Huang